Jan 09, 2026 8:05am EST Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 07, 2025 9:30am EST Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Nov 17, 2025 8:05am EST Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Nov 04, 2025 4:01pm EST Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 03, 2025 9:05am EST Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
Oct 29, 2025 8:05am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
